{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T06:57:42Z","timestamp":1770965862131,"version":"3.50.1"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2011,11,8]],"date-time":"2011-11-08T00:00:00Z","timestamp":1320710400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2011,11,8]],"date-time":"2011-11-08T00:00:00Z","timestamp":1320710400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2012,5]]},"DOI":"10.1038\/leu.2011.315","type":"journal-article","created":{"date-parts":[[2011,11,8]],"date-time":"2011-11-08T09:59:31Z","timestamp":1320746371000},"page":"910-917","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":78,"title":["Synergistic induction of p53 mediated apoptosis by valproic acid and nutlin-3 in acute myeloid leukemia"],"prefix":"10.1038","volume":"26","author":[{"given":"E","family":"McCormack","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I","family":"Haaland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G","family":"Ven\u00e5s","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R B","family":"Forthun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S","family":"Huseby","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G","family":"Gausdal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S","family":"Knappskog","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D R","family":"Micklem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J B","family":"Lorens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00d8","family":"Bruserud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B T","family":"Gjertsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,11,8]]},"reference":[{"key":"BFleu2011315_CR1","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1200\/JCO.2010.30.1820","volume":"29","author":"A Burnett","year":"2011","unstructured":"Burnett A, Wetzler M, Lowenberg B . Therapeutic advances in acute myeloid leukemia. J Clin Oncol 2011; 29: 487\u2013494.","journal-title":"J Clin Oncol"},{"key":"BFleu2011315_CR2","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1016\/S0140-6736(06)69780-8","volume":"368","author":"E Estey","year":"2006","unstructured":"Estey E, Dohner H . Acute myeloid leukaemia. Lancet 2006; 368: 1894\u20131907.","journal-title":"Lancet"},{"key":"BFleu2011315_CR3","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1634\/theoncologist.2008-0100","volume":"13","author":"J Laubach","year":"2008","unstructured":"Laubach J, Rao AV . Current and emerging strategies for the management of acute myeloid leukemia in the elderly. Oncologist 2008; 13: 1097\u20131108.","journal-title":"Oncologist"},{"key":"BFleu2011315_CR4","first-page":"318","volume":"52","author":"I Wojcik","year":"2005","unstructured":"Wojcik I, Szybka M, Golanska E, Rieske P, Blonski JZ, Robak T et al. Abnormalities of the P53, MDM2, BCL2 and BAX genes in acute leukemias. Neoplasma 2005; 52: 318\u2013324.","journal-title":"Neoplasma"},{"key":"BFleu2011315_CR5","doi-asserted-by":"publisher","first-page":"6489","DOI":"10.1038\/sj.onc.1206814","volume":"22","author":"R Claus","year":"2003","unstructured":"Claus R, Lubbert M . Epigenetic targets in hematopoietic malignancies. Oncogene 2003; 22: 6489\u20136496.","journal-title":"Oncogene"},{"key":"BFleu2011315_CR6","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1126\/science.1092472","volume":"303","author":"LT Vassilev","year":"2004","unstructured":"Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 2004; 303: 844\u2013848.","journal-title":"Science"},{"key":"BFleu2011315_CR7","doi-asserted-by":"publisher","first-page":"3150","DOI":"10.1182\/blood-2005-02-0553","volume":"106","author":"K Kojima","year":"2005","unstructured":"Kojima K, Konopleva M, Samudio IJ, Shikami M, Cabreira-Hansen M, McQueen T et al. MDM2 antagonists induce p53-dependent apoptosis in AML: implications for leukemia therapy. Blood 2005; 106: 3150\u20133159.","journal-title":"Blood"},{"key":"BFleu2011315_CR8","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1517\/14656566.9.2.285","volume":"9","author":"T Gerstner","year":"2008","unstructured":"Gerstner T, Bell N, Konig S . Oral valproic acid for epilepsy--long-term experience in therapy and side effects. Expert Opin Pharmacother 2008; 9: 285\u2013292.","journal-title":"Expert Opin Pharmacother"},{"key":"BFleu2011315_CR9","doi-asserted-by":"publisher","first-page":"388","DOI":"10.2174\/138920107783018417","volume":"8","author":"O Bruserud","year":"2007","unstructured":"Bruserud O, Stapnes C, Ersvaer E, Gjertsen BT, Ryningen A . Histone deacetylase inhibitors in cancer treatment: a review of the clinical toxicity and the modulation of gene expression in cancer cell. Curr Pharm Biotechnol 2007; 8: 388\u2013400.","journal-title":"Curr Pharm Biotechnol"},{"key":"BFleu2011315_CR10","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1016\/j.leukres.2008.10.005","volume":"33","author":"A Ryningen","year":"2009","unstructured":"Ryningen A, Stapnes C, Lassalle P, Corbascio M, Gjertsen BT, Bruserud O . A subset of patients with high-risk acute myelogenous leukemia shows improved peripheral blood cell counts when treated with the combination of valproic acid, theophylline and all-trans retinoic acid. Leuk Res 2009; 33: 779\u2013787.","journal-title":"Leuk Res"},{"key":"BFleu2011315_CR11","first-page":"629","volume":"31","author":"F Bellos","year":"2008","unstructured":"Bellos F, Mahlknecht U . Valproic acid and all-trans retinoic acid: meta-analysis of a palliative treatment regimen in AML and MDS patients. Onkologie 2008; 31: 629\u2013633.","journal-title":"Onkologie"},{"key":"BFleu2011315_CR12","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1038\/leu.2010.276","volume":"25","author":"A Quintas-Cardama","year":"2011","unstructured":"Quintas-Cardama A, Santos FP, Garcia-Manero G . Histone deacetylase inhibitors for the treatment of myelodysplastic syndrome and acute myeloid leukemia. Leukemia 2011; 25: 226\u2013235.","journal-title":"Leukemia"},{"key":"BFleu2011315_CR13","doi-asserted-by":"publisher","first-page":"5541","DOI":"10.1038\/sj.onc.1210620","volume":"26","author":"WS Xu","year":"2007","unstructured":"Xu WS, Parmigiani RB, Marks PA . Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene 2007; 26: 5541\u20135552.","journal-title":"Oncogene"},{"key":"BFleu2011315_CR14","doi-asserted-by":"publisher","first-page":"e3062","DOI":"10.1371\/journal.pone.0003062","volume":"3","author":"R Chrisanthar","year":"2008","unstructured":"Chrisanthar R, Knappskog S, Lokkevik E, Anker G, Ostenstad B, Lundgren S et al. CHEK2 mutations affecting kinase activity together with mutations in TP53 indicate a functional pathway associated with resistance to epirubicin in primary breast cancer. PLoS One 2008; 3: e3062.","journal-title":"PLoS One"},{"key":"BFleu2011315_CR15","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/1476-4598-6-33","volume":"6","author":"L Wergeland","year":"2007","unstructured":"Wergeland L, Sjoholt G, Haaland I, Hovland R, Bruserud O, Gjertsen BT . Pre-apoptotic response to therapeutic DNA damage involves protein modulation of Mcl-1, Hdm2 and Flt3 in acute myeloid leukemia cells. Mol Cancer 2007; 6: 33.","journal-title":"Mol Cancer"},{"key":"BFleu2011315_CR16","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/1476-4598-8-101","volume":"8","author":"T Bredholt","year":"2009","unstructured":"Bredholt T, Dimba EA, Hagland HR, Wergeland L, Skavland J, Fossan KO et al. Camptothecin and khat (Catha edulis Forsk.) induced distinct cell death phenotypes involving modulation of c-FLIPL, Mcl-1, procaspase-8 and mitochondrial function in acute myeloid leukemia cell lines. Mol Cancer 2009; 8: 101.","journal-title":"Mol Cancer"},{"key":"BFleu2011315_CR17","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1006\/viro.2000.0353","volume":"272","author":"JB Lorens","year":"2000","unstructured":"Lorens JB, Jang Y, Rossi AB, Payan DG, Bogenberger JM . Optimization of regulated LTR-mediated expression. Virology 2000; 272: 7\u201315.","journal-title":"Virology"},{"key":"BFleu2011315_CR18","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1158\/0008-5472.CAN-09-1947","volume":"70","author":"TC Chou","year":"2010","unstructured":"Chou TC . Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res 2010; 70: 440\u2013446.","journal-title":"Cancer Res"},{"key":"BFleu2011315_CR19","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/nrd1609","volume":"4","author":"CT Keith","year":"2005","unstructured":"Keith CT, Borisy AA, Stockwell BR . Multicomponent therapeutics for networked systems. Nat Rev Drug Discov 2005; 4: 71\u201378.","journal-title":"Nat Rev Drug Discov"},{"key":"BFleu2011315_CR20","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/S0145-2126(01)00151-5","volume":"26","author":"R Kawagoe","year":"2002","unstructured":"Kawagoe R, Kawagoe H, Sano K . Valproic acid induces apoptosis in human leukemia cells by stimulating both caspase-dependent and -independent apoptotic signaling pathways. Leuk Res 2002; 26: 495\u2013502.","journal-title":"Leuk Res"},{"key":"BFleu2011315_CR21","doi-asserted-by":"publisher","first-page":"542","DOI":"10.3324\/haematol.10758","volume":"92","author":"G Bug","year":"2007","unstructured":"Bug G, Schwarz K, Schoch C, Kampfmann M, Henschler R, Hoelzer D et al. Effect of histone deacetylase inhibitor valproic acid on progenitor cells of acute myeloid leukemia. Haematologica 2007; 92: 542\u2013545.","journal-title":"Haematologica"},{"key":"BFleu2011315_CR22","doi-asserted-by":"publisher","first-page":"193","DOI":"10.2310\/7290.2007.00016","volume":"6","author":"E McCormack","year":"2007","unstructured":"McCormack E, Micklem DR, Pindard LE, Silden E, Gallant P, Belenkov A et al. In vivo optical imaging of acute myeloid leukemia by green fluorescent protein: time-domain autofluorescence decoupling, fluorophore quantification, and localization. Mol Imaging 2007; 6: 193\u2013204.","journal-title":"Mol Imaging"},{"key":"BFleu2011315_CR23","doi-asserted-by":"publisher","first-page":"3193","DOI":"10.1158\/0008-5472.CAN-07-2780","volume":"68","author":"K Kumamoto","year":"2008","unstructured":"Kumamoto K, Spillare EA, Fujita K, Horikawa I, Yamashita T, Appella E et al. Nutlin-3a activates p53 to both down-regulate inhibitor of growth 2 and up-regulate mir-34a, mir-34b, and mir-34c expression, and induce senescence. Cancer Res 2008; 68: 3193\u20133203.","journal-title":"Cancer Res"},{"key":"BFleu2011315_CR24","doi-asserted-by":"publisher","first-page":"50607","DOI":"10.1074\/jbc.C200578200","volume":"277","author":"M Li","year":"2002","unstructured":"Li M, Luo J, Brooks CL, Gu W . Acetylation of p53 inhibits its ubiquitination by Mdm2. J Biol Chem 2002; 277: 50607\u201350611.","journal-title":"J Biol Chem"},{"key":"BFleu2011315_CR25","doi-asserted-by":"crossref","unstructured":"Palani C, Beck J, Sonnemann J . Histone deacetylase inhibitors enhance the anticancer activity of nutlin-3 and induce p53 hyperacetylation and downregulation of MDM2 and MDM4 gene expression. Invest New Drugs 2010; e-pub ahead of print 3 August 2010; doi:10.007\/s10637-010-9510-7.","DOI":"10.1007\/s10637-010-9510-7"},{"key":"BFleu2011315_CR26","doi-asserted-by":"publisher","first-page":"810","DOI":"10.4161\/auto.6486","volume":"4","author":"E Tasdemir","year":"2008","unstructured":"Tasdemir E, Chiara Maiuri M, Morselli E, Criollo A, D'Amelio M, Djavaheri-Mergny M et al. A dual role of p53 in the control of autophagy. Autophagy 2008; 4: 810\u2013814.","journal-title":"Autophagy"},{"key":"BFleu2011315_CR27","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1038\/nrm1666","volume":"6","author":"EH Baehrecke","year":"2005","unstructured":"Baehrecke EH . Autophagy: dual roles in life and death? Nat Rev Mol Cell Biol 2005; 6: 505\u2013510.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"BFleu2011315_CR28","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1038\/leu.2008.11","volume":"22","author":"L Gu","year":"2008","unstructured":"Gu L, Zhu N, Findley HW, Zhou M . MDM2 antagonist nutlin-3 is a potent inducer of apoptosis in pediatric acute lymphoblastic leukemia cells with wild-type p53 and overexpression of MDM2. Leukemia 2008; 22: 730\u2013739.","journal-title":"Leukemia"},{"key":"BFleu2011315_CR29","doi-asserted-by":"publisher","first-page":"6236","DOI":"10.1093\/emboj\/cdf616","volume":"21","author":"A Ito","year":"2002","unstructured":"Ito A, Kawaguchi Y, Lai CH, Kovacs JJ, Higashimoto Y, Appella E et al. MDM2-HDAC1-mediated deacetylation of p53 is required for its degradation. Embo J 2002; 21: 6236\u20136245.","journal-title":"Embo J"},{"key":"BFleu2011315_CR30","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1038\/sj.onc.1210707","volume":"27","author":"LM Lau","year":"2008","unstructured":"Lau LM, Nugent JK, Zhao X, Irwin MS . HDM2 antagonist Nutlin-3 disrupts p73-HDM2 binding and enhances p73 function. Oncogene 2008; 27: 997\u20131003.","journal-title":"Oncogene"},{"key":"BFleu2011315_CR31","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1038\/sj.bjc.6603777","volume":"96","author":"RA Blaheta","year":"2007","unstructured":"Blaheta RA, Michaelis M, Natsheh I, Hasenberg C, Weich E, Relja B et al. Valproic acid inhibits adhesion of vincristine- and cisplatin-resistant neuroblastoma tumour cells to endothelium. Br J Cancer 2007; 96: 1699\u20131706.","journal-title":"Br J Cancer"},{"key":"BFleu2011315_CR32","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1182\/blood-2010-01-261628","volume":"116","author":"J Long","year":"2010","unstructured":"Long J, Parkin B, Ouillette P, Bixby D, Shedden K, Erba H et al. Multiple distinct molecular mechanisms influence sensitivity and resistance to MDM2 inhibitors in adult acute myelogenous leukemia. Blood 2010; 116: 71\u201380.","journal-title":"Blood"},{"key":"BFleu2011315_CR33","doi-asserted-by":"publisher","first-page":"33030","DOI":"10.1074\/jbc.C600147200","volume":"281","author":"B Hu","year":"2006","unstructured":"Hu B, Gilkes DM, Farooqi B, Sebti SM, Chen J . MDMX overexpression prevents p53 activation by the MDM2 inhibitor Nutlin. J Biol Chem 2006; 281: 33030\u201333035.","journal-title":"J Biol Chem"},{"key":"BFleu2011315_CR34","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1111\/j.1365-2141.2008.07449.x","volume":"144","author":"FL Khanim","year":"2009","unstructured":"Khanim FL, Bradbury CA, Arrazi J, Hayden RE, Rye A, Basu S et al. Elevated FOSB-expression; a potential marker of valproate sensitivity in AML. Br J Haematol 2009; 144: 332\u2013341.","journal-title":"Br J Haematol"},{"key":"BFleu2011315_CR35","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1038\/sj.leu.2403670","volume":"19","author":"E McCormack","year":"2005","unstructured":"McCormack E, Bruserud O, Gjertsen BT . Animal models of acute myelogenous leukaemia\u2014development, application and future perspectives. Leukemia 2005; 19: 687\u2013706.","journal-title":"Leukemia"},{"key":"BFleu2011315_CR36","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1182\/blood-2005-06-2325","volume":"107","author":"DJ Pearce","year":"2006","unstructured":"Pearce DJ, Taussig D, Zibara K, Smith LL, Ridler CM, Preudhomme C et al. AML engraftment in the NOD\/SCID assay reflects the outcome of AML: implications for our understanding of the heterogeneity of AML. Blood 2006; 107: 1166\u20131173.","journal-title":"Blood"},{"key":"BFleu2011315_CR37","doi-asserted-by":"publisher","first-page":"2222","DOI":"10.1002\/ijc.23772","volume":"123","author":"A Agliano","year":"2008","unstructured":"Agliano A, Martin-Padura I, Mancuso P, Marighetti P, Rabascio C, Pruneri G et al. Human acute leukemia cells injected in NOD\/LtSz-scid\/IL-2Rgamma null mice generate a faster and more efficient disease compared to other NOD\/scid-related strains. Int J Cancer 2008; 123: 2222\u20132227.","journal-title":"Int J Cancer"},{"key":"BFleu2011315_CR38","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.4161\/cc.6.18.4730","volume":"6","author":"G Sarek","year":"2007","unstructured":"Sarek G, Ojala PM . p53 reactivation kills KSHV lymphomas efficiently in vitro and in vivo: new hope for treating aggressive viral lymphomas. Cell Cycle 2007; 6: 2205\u20132209.","journal-title":"Cell Cycle"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/leu2011315.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu2011315","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu2011315.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T14:41:29Z","timestamp":1648737689000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/leu2011315"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,11,8]]},"references-count":38,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2012,5]]}},"alternative-id":["BFleu2011315"],"URL":"https:\/\/doi.org\/10.1038\/leu.2011.315","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,11,8]]},"assertion":[{"value":"8 March 2011","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 August 2011","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2011","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 November 2011","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}